Fusion Antibodies in Talks to Extend NCI Collaboration on OptiMAL Platform

Fusion Antibodies Plc ( (GB:FAB) ) has issued an update.

Fusion Antibodies has reported that the US National Cancer Institute (NCI) wishes to continue using the company’s OptiMAL® human antibody discovery platform as a frontline technology for a range of targets, following a validation project that ran from late 2023 into this year. NCI has submitted a proposal to extend the existing collaboration agreement to cover screening of several specified targets, and discussions held at a recent industry conference in San Diego explored not only support for immediate screening needs but also potential additional projects that could carry enhanced ownership benefits for Fusion. The company cautioned that negotiations around the expanded programme are expected to run into early 2026 and will be subject to lengthy formal approval processes at the US National Institutes of Health, meaning there is no certainty an extension will be concluded or on what terms, but management framed NCI’s interest as a strong validation of OptiMAL® and an encouraging sign for Fusion’s positioning in antibody discovery services.

The most recent analyst rating on (GB:FAB) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.

Spark’s Take on GB:FAB Stock

According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.

Fusion Antibodies Plc receives an overall stock score of 50, primarily driven by its challenging financial performance and valuation concerns. The company’s ongoing profitability and cash flow issues are significant risks. However, the technical analysis indicates strong bullish momentum, which provides some positive sentiment. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on GB:FAB stock, click here.

More about Fusion Antibodies Plc

Fusion Antibodies plc is a Belfast-based contract research organisation specialising in pre-clinical antibody discovery, engineering and supply for therapeutic drug and diagnostic applications. Listed on AIM since 2017, the company offers services spanning antigen expression, antibody discovery via its proprietary OptiMAL® platform, antibody production, purification, sequencing and humanisation through its CDRx™ technology, as well as generating stable cell lines for clinical material. Founded in 2001 as a spin-out from Queen’s University Belfast, Fusion has completed hundreds of sequencing and humanisation projects for an international blue-chip client base, including major global pharmaceutical companies, and focuses on using advanced platforms to accelerate drug development timelines for pharma and biotech customers.

Average Trading Volume: 1,040,684

Technical Sentiment Signal: Buy

Current Market Cap: £18.19M

Learn more about FAB stock on TipRanks’ Stock Analysis page.